Abstract
The prognosis of peritoneal spread from gastrointestinal cancer and subsequent malignant ascites is poor, and current medical treatments available are mostly ineffective. Targeted chemotherapy with intraperitoneal prodrug activation may be a beneficial new approach. L293 cells were genetically modified to express the cytochrome P450 enzyme 2B1 under the control of a cytomegalovirus immediate early promoter. This CYP2B1 enzyme converts ifosfamide to its active cytotoxic compounds. The cells are encapsulated in a cellulose sulfate formulation (Capcell™). Adult Balb/c mice were inoculated intraperitoneally with 1 × 106 colon 26 cancer cells, previously transfected with GFP to emit a stable green fluorescence, by injection into the left lower abdominal quadrant. Two or five day's later animals were randomly subjected to either i.p. treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1-expressing cells. Peritoneal tumor volume and tumor viability were assessed 10 days after tumor inoculation by means of fluorescence microscopy, spectroscopy and histology. Early i.p. treatment with ifosfamide and CYP2B1 cells resulted in a complete response. Treatment starting on day 5 and single-drug treatment with ifosfamide resulted in a partial response. These results suggest that targeted i.p. chemotherapy using a combination of a prodrug and its converting enzyme may be a successful treatment strategy for peritoneal spread from colorectal cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Glehen O, Gilly FN . Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 2003; 12: 649–671.
Glehen O, Osinsky D, Beaujard AC, Gilly FN . Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 2003; 12: 729–739, xiii.
McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD . Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27: 65–73.
McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10: 155–162.
Sugarbaker PH . New responsibilities in the management of colorectal cancer with peritoneal seeding. Cancer Invest 2002; 20: 1118–1122.
Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O et al. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 2002; 99: 130–137.
Dirven HA, van Ommen B, van Bladeren PJ . Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 1996; 9: 351–360.
Kurowski V, Wagner T . Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 1993; 33: 36–42.
Yu LJ, Drewes P, Gustafsson K, Brain EG, Hecht JE, Waxman DJ . In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J Pharmacol Exp Ther 1999; 288: 928–937.
Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C . Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med Oncol 1999; 16: 267–278.
Silbermann MH, vd VB, Stoter G, Nooter K, Verweij J . Combination therapy of ACNU and ifosfamide in tumor bearing mice with M2661 breast cancer, B16 malignant melanoma or C38 colon cancer. Eur J Cancer 1990; 26: 321–325.
Struck RF, Dykes DJ, Corbett TH, Suling WJ, Trader MW . Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Br J Cancer 1983; 47: 15–26.
Bunnell CA, Thompson L, Buswell L, Berkowitz R, Muto M, Sheets E et al. A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 1998; 82: 561–566.
Chen L, Waxman DJ . Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995; 55: 581–589.
Okada N, Miyamoto H, Yoshioka T, Sakamoto K, Katsume A, Saito H et al. Immunological studies of SK2 hybridoma cells microencapsulated with alginate-poly(L)lysine-alginate (APA) membrane following allogeneic transplantation. Biochem Biophys Res Commun 1997; 230: 524–527.
Löhr M, Müller P, Karle P, Stange J, Mitzner S, Jesnowski R et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Therapy 1998; 5: 1070–1078.
Löhr M, Hoffmeyer A, Kröger J, Freund M, Hain J, Holle A et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357: 1591–1592.
Karle P, Müller P, Renz R, Jesnowski R, Saller R, von Rombs K et al. Intratumoral injection of encapsulated cells producing an oxazaphosphorine activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 1998; 451:97–106.
Kammertoens T, Gelbmann W, Karle P, Alton K, Saller R, Salmons B et al. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther 2000; 7: 629–636.
Guide for the Care and Use of Laboratory Animals. National Research Council. Institute of Laboratory Animal Resources. Commission on Life Sciences. Washington DC: National Academy Press; 1996.
Interdisciplinary principles and guidelines for the use of animals in research, testing, and education. A report of the Ad Hoc Committee on Animal Research. NY: Academy of Sciences; 1988.
Sturm JW, Magdeburg R, Berger K, Petruch B, Samel S, Bönninghoff R et al. Influence of TNF alpha on the formation of liver metastases in a syngenic mouse model. Int J Cancer 2003; 107: 11–21.
Sturm JW, Keese MA, Petruch B, Bonninghoff RG, Zhang H, Gretz N et al. Enhanced green fluorescent protein-transfection of murine colon carcinoma cells: key for early tumor detection and quantification. Clin Exp Metastasis 2003; 20: 395–405.
Löhr JM, Saller R, Salmons B, Günzburg WH . Microencapsulation of genetically engineered cells for cancer therapy. Methods Enzymol 2002; 346: 603–618.
Donato MT, Gomez-Lechon MJ, Castell JV . A microassay for measuring cytochrome P450IA1 and P450IIB1 activities in intact human and rat hepatocytes cultured on 96-well plates. Anal Biochem 1993; 213: 29–33.
Beyer WH . CRC Standard Mathematical Table. Boca Raton, FL: CRC Press; 1987.
Gahlen J, Pietschmann M, Prosst RL, Herfarth C . Systemic vs local administration of delta-aminolevulinic acid for laparoscopic fluorescence diagnosis of malignant intra-abdominal tumors. Exp Study. Surg Endosc 2001; 15: 196–199.
Ibrahim SM, Ringel J, Schmidt C, Ringel B, Müller P, Koczan D et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001; 23: 72–79.
Bonenkamp JJ, Sasako M, Hermans J, van de Velde CJ . Tumor load and surgical palliation in gastric cancer. Hepatogastroenterology 2001; 48: 1219–1221.
Elias DM, Pocard M . Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am 2003; 12: 543–559.
Mohamed F, Sugarbaker PH . Peritoneal mesothelioma. Curr Treat Options Oncol 2002; 3: 375–386.
Moran BJ, Cecil TD . The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am 2003; 12: 585–603.
Markman M . Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003; 4: 277–283.
Schwartz PS, Waxman DJ . Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 2001; 60: 1268–1279.
Karle P, Renner M, Salmons B, Günzburg WH . Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther 2001; 8: 220–230.
Zheng JJ, Chan KK, Muggia F . Preclinical pharmacokinetics and stability of isophosphoramide mustard. Cancer Chemother Pharmacol 1994; 33: 391–398.
Jounaidi Y, Hecht JE, Waxman DJ . Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391–4401.
Chen L, Yu LJ, Waxman DJ . Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 1997; 57: 4830–4837.
Jounaidi Y, Waxman DJ . Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 2004; 64: 292–303.
Zagzag D, Miller DC, Chiriboga L, Yee H, Newcomb EW . Green fluorescent protein immunohistochemistry as a novel experimental tool for the detection of glioma cell invasion in vivo. Brain Pathol 2003; 13: 34–37.
Murphy BO, Joshi S, Kessinger A, Reed E, Sharp JG . A murine model of bone marrow micrometastasis in breast cancer. Clin Exp Metastasis 2002; 19: 561–569.
Diehn FE, Costouros NG, Miller MS, Feldman AL, Alexander HR, Li KC et al. Noninvasive fluorescent imaging reliably estimates biomass in vivo. Biotechniques 2002; 33: 1250–1252, 1254–1255.
Gahlen J, Prosst RL, Pietschmann M, Haase T, Rheinwald M, Skopp G et al. Laparoscopic fluorescence diagnosis for intraabdominal fluorescence targeting of peritoneal carcinosis experimental studies. Ann Surg 2002; 235: 252–260.
Acknowledgements
We thank our medical technicians Mrs B Heidrich, Mrs C Jost and Mrs A Gruber from the research lab of the Department of Surgery for providing tumor cells and preparing histological specimens and Mrs N Decker for performing spectroscopy. We thank Bavarian Nordic GmbH, Martinsried, for supplying the Capcell™.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Samel, S., Keese, M., Lux, A. et al. Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide. Cancer Gene Ther 13, 65–73 (2006). https://doi.org/10.1038/sj.cgt.7700849
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700849
Keywords
This article is cited by
-
Intraperitoneal drug delivery systems releasing cytostatic agents to target gastro‐intestinal peritoneal metastases in laboratory animals: a systematic review
Clinical & Experimental Metastasis (2022)
-
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer
Cancer Gene Therapy (2009)
-
Pancreatic cancer — Outlook: gene therapy
The Chinese-German Journal of Clinical Oncology (2007)